198 related articles for article (PubMed ID: 33310286)
21. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
24. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
25. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Lee Walmsley D; Murray JB; Dokurno P; Massey AJ; Benwell K; Fiumana A; Foloppe N; Ray S; Smith J; Surgenor AE; Edmonds T; Demarles D; Burbridge M; Cruzalegui F; Kotschy A; Hubbard RE
J Med Chem; 2021 Jul; 64(13):8971-8991. PubMed ID: 34143631
[TBL] [Abstract][Full Text] [Related]
26. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
Ran K; Zeng J; Wan G; He X; Feng Z; Xiang W; Wei W; Hu X; Wang N; Liu Z; Yu L
Eur J Med Chem; 2021 Aug; 220():113499. PubMed ID: 33940465
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
Wei W; Feng Z; Liu Z; Li X; He H; Ran K; Shi Y; Zhu Y; Ye T; Gao C; Wang N; Yu L
Eur J Med Chem; 2022 Jan; 228():113978. PubMed ID: 34810020
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
[TBL] [Abstract][Full Text] [Related]
30. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
Liu Y; Xia Q; Fang L
Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
35. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
36. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
38. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
[TBL] [Abstract][Full Text] [Related]
39. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
40. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors.
Shuai W; Xiao H; Yang P; Zhang Y; Bu F; Wu Y; Sun Q; Wang G; Ouyang L
J Med Chem; 2024 Apr; 67(8):6425-6455. PubMed ID: 38613499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
